Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Phase 1 Cancer Trials

San Francisco, California

Phase 1 cancer trials in San Francisco, CA

66 Phase 1 cancer studies are recruiting participants at sites in San Francisco as of November 17, 2026, according to ClinicalTrials.gov. Phase 1 Cancer Trials can help you understand your options and connect with a study team.

Call (888) 927-9038
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

San Francisco at a glance

  • 66 studies are recruiting at a site in San Francisco.
  • By phase: Early Phase 1 (4), Phase 1 (33), Phase 1/2 (29).
  • By sponsor: industry (47), university, hospital or other (19).
  • By research area: Prostate Cancer (16), Lung Cancer (14), Breast Cancer (13), Lymphoma (13), Melanoma (7), Pancreatic Cancer (3).
  • Most recent update to one of these records: November 17, 2026.

Breast cancer studies recruiting in San Francisco

Basic details from each study's public record (the 30 most recently updated of 66). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Stemline Therapeutics, Inc.
    Study site
    UCSF Helen Diller Family Comprehensive Cancer Center
    Registry record
    NCT06638307 · updated
  2. Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    ORIC Pharmaceuticals
    Study site
    University of California, San Francisco
    Registry record
    NCT05315700 · updated
  3. A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

    • Phase 1/2
    • Ages 18 and older
    • Female participants
    Sponsor
    Hoffmann-La Roche
    Study site
    University of California, San Francisco (UCSF)
    Registry record
    NCT04802759 · updated
  4. A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Genentech, Inc.
    Study site
    UCSF Helen Diller Family CCC
    Registry record
    NCT07100106 · updated
  5. Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Aminex Therapeutics, Inc.
    Study site
    University of California-San Fransisco
    Registry record
    NCT07287917 · updated
  6. Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    AbbVie
    Study site
    UCSF Medical Center - Mount Zion /ID# 257705
    Registry record
    NCT06084481 · updated
  7. Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Ensem Therapeutics
    Study site
    UCSF Helen Diller Family Comprehensive Cancer Center
    Registry record
    NCT06993844 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in San Francisco, CA on ClinicalTrials.gov.

Lung cancer studies recruiting in San Francisco

  1. Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Vivace Therapeutics, Inc
    Study site
    UCSF Helen Diller Family Comprehensive Cancer Center
    Registry record
    NCT04665206 · updated
  2. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Institut de Recherches Internationales Servier
    Study site
    University of California, San Francisco (UCSF)
    Registry record
    NCT05786924 · updated
  3. A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Bayer
    Study site
    UCSF Helen Diller Medical Center at Parnassus Heights - Neurology
    Registry record
    NCT06914128 · updated
  4. Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    SystImmune Inc.
    Study site
    UCSF- San Francisco (Helen Diller Family Comprehensive Cancer Center)
    Registry record
    NCT07080242 · updated
  5. A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    TRIANA Biomedicines, Inc.
    Registry record
    NCT07491497 · updated
  6. Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    UCSF Helen Diller Family Comprehensive Cancer Center
    Registry record
    NCT07397338 · updated
  7. Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Tango Therapeutics, Inc.
    Study site
    University of California at San Francisco
    Registry record
    NCT06810544 · updated
  8. Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    UCSF Medical Center - Mission Bay
    Registry record
    NCT06162221 · updated
  9. A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Frontier Medicines Corporation
    Study site
    University of California San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center
    Registry record
    NCT06244771 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in San Francisco, CA on ClinicalTrials.gov.

Prostate cancer studies recruiting in San Francisco

  1. Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer

    • Phase 1
    • Ages 18 and older
    • Male participants
    Sponsor
    Astellas Pharma Global Development, Inc.
    Study site
    University of California
    Registry record
    NCT05997615 · updated
  2. Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

    • Phase 1
    • Ages 18 and older
    • Male participants
    Sponsor
    Amgen
    Study site
    University of California San Francisco
    Registry record
    NCT04221542 · updated
  3. 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer

    • Phase 1
    • Ages 18 and older
    • Male participants
    Sponsor
    University of California, San Francisco
    Study site
    University of California, San Francisco
    Registry record
    NCT07145177 · updated
  4. Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

    • Phase 1
    • Ages 18 to 100
    • Male participants
    Sponsor
    Janux Therapeutics
    Study site
    UCSF Helen Diller Family Comprehensive Cancer Center
    Registry record
    NCT05519449 · updated
  5. A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

    • Phase 1
    • Ages 18 and older
    • Male participants
    Sponsor
    K36 Therapeutics, Inc.
    Study site
    University of California San Francisco
    Registry record
    NCT07103018 · updated
  6. Magnetic Resonance (MR) Imaging With Hyperpolarized Bicarbonate (13C) to Measure Tissue pH in Prostate Cancer

    • Early Phase 1
    • Ages 18 and older
    • Male participants
    Sponsor
    Robert Flavell, MD, PhD
    Study site
    University of California, San Francisco
    Registry record
    NCT05851365 · updated
  7. A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    UCSF Medical Center at Mission Bay ( Site 0034)
    Registry record
    NCT06863272 · updated
  8. FOG-001 in Locally Advanced or Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Parabilis Medicines, Inc.
    Study site
    University of California San Francisco, Helen Diller Family Comprehensive Cancer Center
    Registry record
    NCT05919264 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in San Francisco, CA on ClinicalTrials.gov.

Melanoma studies recruiting in San Francisco

  1. A Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.

    • Phase 1
    • Ages 18 and older
    • Female participants
    Sponsor
    Outpace Bio, Inc.
    Study site
    UCSF - Helen Diller Family Comprehensive Cancer Center
    Registry record
    NCT07664735 · updated
  2. A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Relay Therapeutics, Inc.
    Study site
    University of California, San Francisco
    Registry record
    NCT07584226 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in San Francisco, CA on ClinicalTrials.gov.

Lymphoma studies recruiting in San Francisco

  1. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

    • Phase 1/2
    • Up to age 22
    • All sexes
    Sponsor
    PedAL BCU, LLC
    Study site
    UCSF Medical Center-Mission Bay
    Registry record
    NCT04726241 · updated
  2. A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center
    Registry record
    NCT07226843 · updated
  3. Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

    • Phase 1
    • From 24 months, up to 18 years
    • All sexes
    Sponsor
    ITM Solucin GmbH
    Study site
    UCSF Benioff Children's Hospital
    Registry record
    NCT06441331 · updated
  4. Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    C. Babis Andreadis
    Study site
    University of California, San Francisco
    Registry record
    NCT04545762 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in San Francisco, CA on ClinicalTrials.gov.

Ask about studies near San Francisco

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in California

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 1, including early Phase 1 and combined Phase 1/2, as each study is coded in the registry.

Phase 1 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-9038

or send a short form

How should we reach you?

Call